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ABSTRACT
NHANES measured folate and vitamin B-12 status biomarkers, start-
ing with serum folate from NHANES I (1974–1975) through 2010.
Subsequent NHANES measured additional biomarkers [eg, red blood
cellfolate,serumvitaminB-12,totalhomocysteine(tHcy),methylma-
lonic acid, serum folic acid, and 5-methyltetrahydrofolic acid]. Exam-
plesoftheusesofthesedataarewiderangingandincludepublicpolicy
applications, the derivation of reference intervals, and research. Peri-
odically, the National Center for Health Statistics and its federal part-
ners convene expert panels to review the use of the folate- and vitamin
B-12–related biomarkers in NHANES. These panels have evaluated
the need for results to be comparable across time and with published
data and the use of crossover studies and adjustment equations to en-
sure comparability. With the recent availability of reference methods
and materials for serum folate and tHcy, NHANES has started to use
traceability approaches to enhance the accuracy and comparability of
its results. A major user concern over the years has been the use of
cutoffs to estimate the prevalence of inadequate folate and vitamin
B-12 status. Because these cutoffs depend on the measurement proce-
dure, several expert panels suggested approaches for dealing with cut-
off challenges. This review summarizes the history and use of folate-
and vitamin B-12–related biomarkers beginning with NHANES I
(1974–1975) through 2010. Am J Clin Nutr 2011;94(suppl):1S–
10S.
INTRODUCTION
NHANES provides nationally representative information on the
US population’s health and nutritional status (1–3). The survey col-
lects information with the use of interviews, medical and physical
examinations,andclinicaltestsunderstandardizedconditionsthrough
home interviews and at mobile medical examination centers. The
Centers for Disease Control and Prevention (CDC) conducted these
surveys periodically between 1974 and 1994 (NHANES I in 1974–
1975; NHANES II in 1976–1980; and NHANES III in 1988–1994)
and has conducted them continuously since 1999. The ﬁndings
provide the basis for national reference standards for measurements
suchasheight,weight,andbloodpressure.Researchersalsousethese
data to assess the prevalence of major diseases and inadequate or
excessive nutritional status among US population groups and to
identify correlates of these disease and health risks.
TheCDC’sNationalCenterforHealthStatistics(NCHS)isthe
agencyresponsibleforNHANES.Interrelatedchangesinscience,
userneeds,andpopulation-basedenvironmentsoccurconcurrently
but independently across survey time spans. The NCHS must
therefore update and revise NHANES content and measurement
procedures frequently and in a manner that addresses user needs
while it maintains sound science within the survey’s mission, re-
source, and logistic limits. To help with this effort, the NCHS and
the Ofﬁce of Dietary Supplements of the National Institutes of
Health recently convened a roundtable expert panel to review the
scientiﬁc and public health issues involved in past, current, and
futuremeasurementoffolateandvitaminB-12statusbiomarkersin
NHANES. Other articles in this supplement discuss the results of
the roundtable dialogue (4, 5) and provide an overview of the
various roundtable components (6). The current article describes
the history and use of these biomarkers in past and current
NHANES.Whenwepresentserumandredbloodcell(RBC)folate
datainthisarticle,weexpressvaluesinnmol/L(1.0ng/mL=2.266
nmol/L).
HISTORY OF FOLATE- AND VITAMIN B-12–RELATED
BIOMARKERS IN NHANES
Nutritional status biomarkers are important for the assessment
of population groups’ nutritional status. The classic folate status
biomarkers include serum and RBC folate (7, 8). The vitamin
B-12 status biomarkers include serum vitamin B-12 and meth-
ylmalonic acid (MMA) (7, 9). Total homocysteine (tHcy) is
a nonspeciﬁc indicator of vitamin B-12 and folate inadequacies
(7, 9). Serum folate and vitamin B-12 are direct measures of
circulating blood concentrations, and RBC folate reﬂects intakes
over the past 90–120 d (4, 7). MMA and tHcy are functional
indicators of status because they measure metabolites that ac-
cumulate as a result of deﬁciencies in the vitamins that their
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serum folic acid (FA) concentrations (also referred to as serum
unmetabolized FA in some cited references) because of concerns
that increased exposures to the synthetic FA in fortiﬁed foods and
dietary supplements may elevate serum concentrations of this
folate vitamer and that this may raise safety concerns (10–14).
NHANES has a long history of measurement of folate- and vi-
tamin B-12–related biomarkers (Table 1). The ﬁrst NHANES
(1974–1975)measuredserumfolate,andNHANESII(1976–1980)
added RBC folate and serum vitamin B-12 measurements. Mea-
surement of the 2 folate variables has continued through 2010.
Various NHANES have measured serum vitamin B-12, tHcy,
MMA, and folate vitamers (5-methyltetrahydrofolate and FA) for
several survey periods. NHANES 2007–2010 did not measure se-
rum vitamin B-12 and tHcy, and NHANES did not measure MMA
in 2005–2010.
The reasonsfortheadditionofthedifferentfolate-andvitamin
B-12–related biomarkers to NHANES have varied as public
health concerns changed and measurement techniques improved.
NHANES I (1974–1975) and II (1976–1980) initially measured
serum and RBC folate to provide an interpretive aid in the eval-
uation of abnormal hematologic indexes (15). An expert panel that
reviewed NHANES II nutritional biomarker data in 1984 found
that the availability of data on these 2 biomarkers offered an
opportunity to examine the prevalence of persons at risk of in-
adequate folate status (15). Subsequently, interest in monitoring
the folate status of US population groups increased because of the
opportunity to assess status changes associated with the 1998
implementation of the FA fortiﬁcation program (16). In the
postfortiﬁcation era, the focus of the interest in monitoring folate
status has shifted from inadequacy to the safety of excessive
intakes (4).
NHANES II (1976–1980) was the ﬁrst NHANES to measure
serum vitaminB-12. At that time, the measurement procedure for
serumandRBCfolatechangedfromamicrobiologicalassay(MA)
to the Bio-Rad Quantaphase I competitive protein binding mea-
surement procedure (Bio-Rad Laboratories, Hercules,CA) (Table
1). Thiskit allowed measurement of bothserum vitamin B-12 and
folate. Subsequently, interest increased in monitoringvitaminB-
12 status following the implementation of FA fortiﬁcation in 1998
TABLE 1
History of measurement of indicators of folate and vitamin B-12 status in NHANES
1
Measure
Measurement
procedure Matrix Laboratory Population age group
Serum and RBC folate
NHANES I (1974–1975) MA Serum NCEH 25–74 y
NHANES II
1976–1978 MA Serum, WB NCEH 6 mo–74 y
1978–1980 Bio-Rad I Serum, WB NCEH 6 mo–74 y
NHANES III
1988–1991 Bio–Rad I Serum, WB NCEH 4y
1991–1994 Bio-Rad II Serum, WB NCEH 4y
NHANES 1999–2002 Bio-Rad II Serum, WB NCEH 3y
NHANES 2003–2006 Bio-Rad II Serum, WB NCEH 1y
NHANES 2007–2010 MA Serum, WB NCEH 1y
LC-MS/MS Serum, WB NCEH One-third subset, 1y
FA and 5-MTHF
NHANES 1999–2002 Afﬁnity/HPLC Surplus serum Tufts 60 y
NHANES 2007–2010
2 LC-MS/MS Serum, WB NCEH One-third subset, 1y
Serum vitamin B-12
NHANES II (1976–1980) Bio-Rad I Serum NCEH 6 mo–74 y (subset)
NHANES III (1991–1994) Bio-Rad II Serum NCEH 4y
NHANES 1999–2002 Bio-Rad II Serum NCEH 3y
NHANES 2003–2006 Bio-Rad II Serum NCEH 1y
Total homocysteine
NHANES III (1991–1994) HPLC-FD Surplus serum Tufts 12 y
NHANES 1999–2001 FPIA IMx Plasma NCEH 3y
NHANES 2002–2004 FPIA AxSYM Plasma NCEH 3y
NHANES 2005–2006 FPIA AxSYM Plasma NCEH 20 y
Methylmalonic acid
NHANES III (1988–1994) GC/MS Surplus serum Tufts 30–39 y, 65 y
NHANES 1999–2004 GC/MS Plasma NCEH 3y
1 RBC, red blood cell; MA, microbiological assay; NCEH, National Center for Environmental Health, Centers for
Disease Control and Prevention; WB, whole-blood lysate; Bio-Rad I, Bio-Rad Quantaphase I commercial kit (Bio-Rad
Laboratories, Hercules, CA); Bio-Rad II, Bio-Rad Quantaphase II commercial kit; LC-MS/MS, liquid chromatography–
tandem mass spectrometry; FA, serum folic acid (also referred to as serum unmetabolized folic acid); 5-MTHF, 5-meth-
yltetrahydrofolic acid; Tufts, Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at
Tufts University, Boston, MA; GC/MS, gas chromatography/mass spectrometry; HPLC-FD, HPLC-ﬂuorescence detection;
FPIA IMx, commercial ﬂuorescence polarization immunoassay reagent set (Abbott Laboratories, Abbott Park, IL) on the
Abbott IMx analyzer; FPIA AxSYM, commercial ﬂuorescence polarization immunoassay reagent set (Abbott Laboratories)
on the Abbott AxSYM analyzer.
2 Includes measurement of other folate vitamers, in addition to FA and 5-MTHF.
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vitamin B-12 status (16). Post–FA fortiﬁcation measurement of
serum vitamin B-12 continued until NHANES 2006; NHANES
subsequently stopped the measurement of serum vitamin B-12
becausethemanufacturerstoppedproductionoftheBio-Radkit,and
serumvitamin B-12 concentrations had not shownany appreciable
changesinNHANESsurveysconductedbetween1991and2006(4).
Researchers at the Jean Mayer US Department of Agriculture
Human Nutrition Research Center on Aging at Tufts University
initially measured tHcy, MMA, and folate vitamers with the use
of stored surplus sera from prior NHANES as special research
projects (Table 1) (12, 17, 18). After the researchers established
these biomarkers’ measurement capability for large surveys such
asNHANES,andbecauseofpublichealthprioritiesformonitoring
the US population’s folate and vitamin B-12 status, several
NHANES survey periods subsequently included these biomarkers,
and the CDC’sNational Center for Environmental Health(NCEH)
generated these data (Table 1).
Periodically, the NCHS and its federal partners convene expert
panels to review the quality of the measurement procedures and
the interpretation of NHANES nutritional status data (15, 19,20).
The recent roundtable panel continued this process for folate and
added a review of vitamin B-12–related biomarkers (4, 5).
USES OF NHANES
A range of policy, research, industry, and consumer groups
uses NHANES data for a variety of applications. We provide
examples of several key applications below.
Public policy applications
AhighlyvisibleandmajoruseofNHANESnutritionaldataisto
support the development and evaluation of public health policies
and programs. The inclusion of folate and vitamin B-12 status
indicators in NHANES before and after the 1998 FA fortiﬁcation
policy’s implementation is an excellent case study of the use of
NHANESdataforpublichealthpolicydecisions(16,21,22).The
NHANES distribution data for folate- and vitamin B-12–related
biomarkers provided useful baseline and time-trend information
for the development and monitoring of the FA fortiﬁcation pro-
gram.TheNHANESdatashowedmarkedshiftsinthedistributions
of serum (Figure 1A) and RBC folate (Figure 1B), but not serum
vitamin B-12 (Figure 1C), before and after fortiﬁcation. Post-
fortiﬁcation distributions were relatively stable. Because the for-
tiﬁcation program involved the addition of FA, but not vitamin
B-12, to enriched foods, these ﬁndings are consistent with ex-
pectations. The biomarker distributions and their changes over
time allow an evaluation of whether the desired improvements in
status occurred at the low end of the distribution curve (ie, a de-
crease of inadequate or low folate status) and of the potential for
concern at the high end of the distribution curve (ie, increases in
folate values associated with potentially excessive intakes) be-
tween 2 time periods.
tHcy, a nonspeciﬁc indicator of inadequate folate status, also
shifted between the pre- and postfortiﬁcation time periods
(Figure 2). tHcy accumulates with folate inadequacy but is
relatively stable across normal folate ranges. As a result, the
change from before and after fortiﬁcation is limited to the tail on
the right side of the distribution curve, as we would expect with
a decrease in the prevalence of low folate status.
The combination of data from several national data sets helps
one more fully evaluate health changes associated with FA for-
tiﬁcation.TheFAfortiﬁcationprogram’spurposewastodecrease
theincidenceofneuraltubebirthdefects,suchasspinabiﬁda(16,
21, 22). The combination of the data on RBC folate from the
NHANES with the spina biﬁda incidence rates from the Vital
Statistics data shows the national trends in folate status and spina
biﬁda rates before and after fortiﬁcation (Figure 3).
The discovery of consistent and expected changes in multiple
biomarker measures (ie, serum and RBC folate, tHcy, serum
vitamin B-12) provides greater conﬁdence than if only one
indicator of nutrient status is available. Agencies frequently
implementpublic policydecisions, suchasthose involvedin the
design and implementation of the FA fortiﬁcation program,
within a context of considerable uncertainty about the likely
magnitude of their effectiveness or the possibility of triggering
unintended and unknown safety concerns. Therefore, national
monitoring programs such as NHANES are often the best, and in
FIGURE 1. Mountain plots of serum folate (A), red blood cell (RBC)
folate (B), and serum vitamin B-12 (C). All 3 ﬁgures represent the total
population of the United States according to NHANES, which spanned 1988–
1994, 1999–2000, 2001–2002, 2003–2004, and 2005–2006. The vertical dotted
lines indicate commonly used cutoffs for assessment of low serum and RBC
folate and serum vitamin B-12. For serum and RBC folate, 1 ng/mL = 2.266
nmol/L. Panels A and B are updated versions of Figure 1 in reference 22, and
panel C is an updated version of Figure 2 in reference 21 to include NHANES
data published subsequent to these earlier publications (C Pfeiffer, personal
communication, 2011).
FOLATE AND VITAMIN B-12 STATUS BIOMARKERS 3Ssome cases the only, practical way to monitor the population-
based effects of national policy interventions (16, 24).
Reference intervals
NHANES data are also useful for the development of pop-
ulation-based reference intervals. Clinical laboratories, health
professionals, and researchers use these data as a basis for
comparisons to evaluate their own laboratory, patient, or group
data. The CDC’s growth charts, which the CDC derived from
NHANES anthropometric data, are a well-known example of the
use of NHANES-supported reference data (25, 26). For folate-
and vitamin B-12–related biomarkers, the CDC and others have
published reference intervals, beginning with the NHANES III
data set (1988–1994) and continuing through recent surveys (18,
22, 23, 27–30). Similar to public policy applications, this ap-
plication of NHANES data uses both distribution curves and
measures of central tendency.
Research and other applications
Researchers frequently use NHANES nutrient biomarker and
other data to identify groups at risk of various diseases and
health conditions and to determine correlates of disease risk.
Researchers use the results for a variety of purposes, such as the
generation of hypotheses, the identiﬁcation of research needs,
and the identiﬁcation of modiﬁers of nutritional and disease risk.
Studies have used NHANES data to examine relations between
folate and vitamin B-12 status biomarkers and a variety of health
and disease conditions. These conditions include cardiovascular
risk and ﬁtness (31–38), obesity and weight loss (39, 40), lead and
neurobehavioral test performance (41), tobacco exposure (42, 43),
anemia and cognitive function (12, 44–46), hypothyroidism (47),
dentalandperiodontalhealth(48,49),coloncancer(50),andgene-
gene and gene-nutrient interactions (51). Evaluations of associa-
tions betweenintakes and/ordemographic variables and folate and
vitamin B-12 status are also common (10, 52–54). Because results
from the NHANES and other observational studies indicated that
B vitamin status was associated with a decreased risk of cardio-
vascular disease, researchers were able to obtain funding for several
large randomized clinical trials (55).
COMPARABILITY ISSUES FOR NHANES BIOMARKERS
Now that researchers have .3 decades of experience with
NHANES nutrient biomarker data, the comparability of bio-
marker measurements over time and with published data has
been a constant measurement and interpretability challenge for
the NCHS and the analytic laboratories that generate the data,
as well as for NHANES data users. The recent and evolving
availability of reference methods and materials will provide
useful tools for tracing results from a given NHANES laboratory
or measurement procedure to a commonly accepted reference
point, which will provide a basis for marked progress in the
resolution of these challenges (4, 5, 56–59).
Comparability of NHANES results across time
NHANES has existed since 1971, NHANES 2011–2012 is
currently in the ﬁeld, and plans for NHANES 2013–2014 are
underway. With its long timelines, the survey must constantly
adapt to inevitable scientiﬁc improvements in the measurement
procedures for a given biomarker (Table 1). These changes con-
sistently raise questions about whether differences in biomarker
concentrations from one survey period to the next (or even within
a single survey period if measurement procedures change or assay
drift occurs) are due to methodologic artifacts or reﬂect true
population changes in nutrient status (15, 20–23, 58, 60, 61). The
lack of a sound basis for measurement comparability across time
jeopardizes a major design component of the NHANES, that of
time-trend analyses. The current roundtable reviewed the most
recent time-trend challenge, how to deal withdifferences inresults
between the Bio-Rad Quantaphase II assay used to measure serum
and RBC folates in NHANES 1991–1994 and 1999–2006 and
the MA used to measure these biomarkers in NHANES 2007–
2010 (4).
When changes in measurement procedures occur, as with
folate- and vitamin B-12–related biomarkers (Table 1), NHANES’
laboratories commonly conduct crossover studies that measure the
same samples with the use of both the “new” and “old” mea-
surement procedures (20–23, 61–63). From the results of these
studies, the NCHS can derive statistical equations to adjust (also
referred to as “correct” in some publications) the values from one
measurementproceduretoreﬂectthevaluesitwouldhaveobtained
with the second procedure (Table 2). In many cases, expert panels
have reviewed and concurred with the use of these adjustment
equations, and have often noted that time-trend analyses would be
FIGURE 2. Mountain plots of plasma total homocysteine (Hcy) in the
total US population (with the exclusion of persons with chronic kidney
disease) according to NHANES, which spanned 1991–1994, 1999–2000,
2001–2002, and 2003–2004. This is an updated version of Figure 2 in
reference 23 to include NHANES data published subsequent to this
earlier publication (C Pfeiffer, personal communication, 2011).
FIGURE 3. Comparison of median red blood cell (RBC) folate values
and spina biﬁda incidence rates that spanned NHANES 1988–1994, 1999–
2000, 2001–2002, 2003–2004, and 2005–2006. For RBC folate, 1 ng/mL =
2.266 nmol/L (C Johnson, personal communication, 2011).
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procedure differences (4, 5, 15, 20, 58). For example, an expert
panel that reviewed the change from the Bio-Rad Quantaphase I
to a Bio-Rad Quantaphase II measurement procedure midway
through NHANES III (1988–1994) noted differences in serum
and RBC concentrations between the 2 laboratory methods (20).
The panel recommended the use of a statistical adjustment equa-
tion based on a crossover study to adjust the Quantaphase I results
to concentrations that would have been obtained with the Quanta-
phase II procedure (Table 2). The application of this statistical
equation to the unadjusted serum and RBC data systematically
decreased values across the distribution curve by ’35% for serum
and ’30% for RBC folate (Table 3) (20). In another example, the
NCEH and NCHS identiﬁed 3 adjustment equations to compare
tHcy in NHANES III (1988–1994) and NHANES 1999–2004
data because the 2 surveys used different measurement proce-
dures and laboratories to perform the analyses, as well as a dif-
ferent sample matrix (Tables 1 and 2) (23, 61).
However, in a few cases, experts could not ﬁnd a statistical
model with a good data ﬁt between the measurement proce-
dures of interest (15). For example, an expert panel did not ﬁnd
asatisfactorystatisticalmodeltoadjusttheserumandRBCfolate
results to convert the MA data to Bio-Rad Quantaphase I pro-
cedure data in NHANES II (1978–1980) (15). Instead, the panel
recommended merging the data from the 2 measurement pro-
cedures for concentrations at the lower half of the distribution
curves (,14 nmol/L for serum folate and ,340 nmol/L for RBC
folate) but not for distributions above these values (Table 2). The
panel based this recommendation on the observation that the
results of the 2 measurement procedures below these cutoffs
were similar but the distributions above these cutoffs diverged
substantially. This approach enabled computations of the preva-
lence of low folate values from the merged data for both mea-
surement procedures, but the merged data could not provide group
means. Currently, an evaluation of statistical models to relate the
Bio-Rad Quantaphase II serum and RBC folate results from
NHANES 1999–2006 to the MA results from NHANES 2007–
2008 is underway (62).
In some cases, NCHS has adjusted the NHANES data sets for
measurement procedure differences before their release; in other
cases, users need to make these adjustments as part of their data
analysis (Table 2). Web-based NCHS NHANES documentation
and guidance documents are available to inform users about the
needtoapplyastatisticaladjustmentequationfortheirtime-trend
analyses.
Comparability with reference methods and materials
(“traceability”)
In the development and reﬁning of measurement procedures,
laboratory scientists strive for both precision (reproducibility)
and accuracy (trueness) (57, 59). Accuracy is the ultimate goal
because it incorporates components necessary for both precision
and comparability. Scientists evaluate precision by the assessment
of variability with the use of replicate measures and monitoring of
the stability of quality control pools over time. Information on the
precision and other performance characteristics of NHANES
measurement procedures for all measured biomarkers, which
includes those for folate and vitamin B-12 assessments, is part of
the documentation of each NHANES (4, 5).
Accuracy, the ultimate measurement goal, has historically
been more difﬁcult to assess than precision (59). The multiple
expert panels convened to review folate biomarkers in NHANES
have generally considered the MA to be the “gold standard”
measurement procedure for serum and RBC folates because it
fully measures the multiple forms of folate species that exhibit
folate vitamin activity and does not measure folate species that
lack vitamin activity (4, 8, 15). The competitive protein binding
commercial assay kits have not always measured all biologically
active species accurately. Measurement of folate vitamers in
a manner that reﬂects their in vivo concentrations has been
a challenge for the more recent liquid chromatography–tandem
mass spectrometry measurement procedures because of inter-
conversions and degradation of some of the vitamers during
sample handling and processing (4, 8).
NHANES analytic laboratories, along with the broader sci-
entiﬁc community, are beginning to deﬁne accuracy with the use
ofa“traceability”processthatlinkstheresultsfromanindividual
sample to a formally accepted, well-documented reference
method (57, 59). Traceability is independent of the measurement
system, location, or time of analysis. The National Institute of
Standards and Technology (NIST) and the NCEH have received
formal recognition for their measurement procedures for serum
5-methyltetrahydrofolate, FA, and tHcy as reference methods
from the Joint Committee on Traceability in Laboratory Methods
(64). The NIST has also made available standard reference ma-
terialswithcertiﬁedvaluesforserum5-methyltetrahydrofolateand
tHcy, reference values for serum FA, and method-speciﬁc in-
formation values for total serum folate and serum vitamin B-12
(65). The NIST is developing a standard reference material for
plasma MMA and serum vitamin B-12 (5).
When the serum-based NIST Standard Reference Materials
1955 became available in 2006, NCEH was able to compare
results from the NHANES Bio-Rad Quantaphase II procedure
with the NIST information values for serum total folate by liquid
chromatography–tandem mass spectrometry and MA. The Bio-
Rad results were 25–40% lower (4). The National Institute for
Biological Standards and Control has a reference material for
RBC folate (95/528) with consensus values from various MA and
protein binding measurement procedures. The Bio-Rad results on
this material were 45% lower than the consensus value (4). Thus,
the availability of external reference materials showed that the
Bio-Rad procedures raised accuracy concerns. With conversion
to the MA in 2007, NCEH results for serum folatewere similar to
the assigned values for the reference materials. To ensure that
measurement procedures do not shift over time, NCEH has
continuously used available reference materials for periodic
checks, so-called calibration veriﬁcations. As mass-spectrometry-
based measurement procedures become more available for routine
use, the NCEH is incorporating higher-order reference measure-
ment procedures into NHANES analytic procedures.
Comparability of NHANES results with other published
data
NHANESdatausersfrequentlyneedorwanttocompareNHANES
results with other published data. These comparisons require an un-
derstanding of the comparability of results from different measure-
ment procedures, and this information is often not available. For
example,StatisticsCanadarecentlyreleasedtheresultsofitsCanadian
FOLATE AND VITAMIN B-12 STATUS BIOMARKERS 5SHealth Measures Survey for 2007–2009 (66). Comparisons of the
Canadian 2007–2008 results with NHANES 2003–2006 results for
adults aged 20–70 y showed differences in medians for RBC folate
(1266 for Canada compared with 603 nmol/L for the United States),
plasma tHcy (6.7 compared with 8.0 lmol/L), and serum vitamin B-
12 (299 compared with 339 pmol/L) (C Stempos, personal com-
munication, 2011). Health Canada and NCEH used different mea-
surementprocedurestoobtaintheirbiomarkerresults.Withoutdirect
TABLE 2
Adjustment equations to allow comparison of folate- and vitamin B-12–related biomarker results across NHANES when measurement procedure
changes occurred
1
Measure Survey Conversion Measurement procedure adjustment Who?
2 References
Serum folate NHANES II
1978–1980
MA to Bio-Rad I To obtain a national probability sample,
merge the 2 data sets only for
values ,6 ng/mL (14 nmol/L);
3 for
values 6 ng/mL, data sets cannot be
merged and nationally representative
means cannot be calculated
User (15)
NHANES III
1988–1994
Bio-Rad I to Bio-Rad II Adjusted value (Bio-Rad I) = 20.1411 +
0.6849 · (unadjusted value Bio-Rad I)
NCHS (20) and (28)
1991–2010 Bio-Rad II to MA Adjustment information in press User (61)
RBC folate NHANES II MA to Bio-Rad I To obtain a national probability sample,
merge the 2 data sets only for
values ,150 ng/mL (340 nmol/L)
3
User (15)
1978–1980 For values 150 ng/mL, data sets cannot
be merged and nationally representative
means cannot be calculated
——
NHANES III
1988–1994
Bio-Rad I to Bio-Rad II Adjusted value (Bio-Rad I) = 20.1411 +
0.6849 · (unadjusted value Bio-Rad I)
NCHS (20) and (28)
1991–2010 Bio-Rad II to MA Adjustment information in press User (61)
Serum vitamin B-12 1976–1980
compared
with 1991–2006
Bio-Rad I to Bio-Rad II No adjustment needed
Total homocysteine 1991–1994 Tufts HPLC serum to
Tufts HPLC plasma
Log10 Tufts HPLC plasma = 1.042 ·
log10 Tufts HPLC serum – 0.079; r = 0.98;
95% CI for slope: 0.957, 1.126; 95% CI
for intercept: 20.156, 20.002
User (23)
Tufts HPLC plasma to
NCEH HPLC plasma
Log10 NCEH HPLC = 1.165 · log10 Tufts
HPLC plasma – 0.120; r = 0.97; 95% CI
for slope: 1.110, 1.220; 95% CI for
intercept: 20.170, 20.070
User (23)
NCEH HPLC plasma
to AxSYM plasma
Log10 AxSYM = 1.104 · log10 NCEH
HPLC – 0.006; r = 0.99; 95% CI for slope:
0.998, 1.029; 95% CI for intercept: 20.020,
0.0008
User (23)
1999–2000 and 2001 IMx to AxSYM Log10 AxSYM = 0.983 · log10 IMx + 0.042;
r = 0.99; 95% CI for slope:0.969, 0.997; 95%
CI for intercept: 0.030, 0.054
User (23)
2002 and 2003–2004 AxSYM No conversion needed — —
MMA 1988–1994 to
1999–2004
Tufts serum to NCEH plasma No formal MMA method comparison was
conducted, which precluded direct comparison
of the MMA results between these 2 surveys
User (21)
Serum creatinine
4 1988–1994 to
1999–2000
Jaffe ´ method (kinetic alkaline
picrate) to Roche enzymatic
assay traceable to reference
measurement procedures
Adjusted serum creatinine (Y) = 0.147 +
1.013 · unadjusted serum creatinine (mg/dL);
(slope was not statistically signiﬁcantly
different from 1.0 and intercept was not
statistically different from 0)
User (63)
1 MA, microbiological assay; Bio-Rad I, Bio-Rad Quantaphase I commercial assay kit (Bio-Rad Laboratories, Hercules, CA); Bio-Rad II, Bio-Rad
Quantaphase II commercial assay kit; NCHS, National Center for Health Statistics, the Centers for Disease Control and Prevention; RBC, red blood cell;
Tufts, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA; NCEH, National Center for Environmental Health,
Centers for Disease Control and Prevention; AxSYM, Abbott AxSYM analyzer (Abbott Laboratories, Abbott Park, IL); ImX, Abbott ImX analyzer (Abbott
Laboratories); MMA, methylmalonic acid.
2 “Who?” refers to whether the statistical adjustment should be done by the user of the NHANES data, or NCHS incorporated the adjustment into the data
set prior its public release.
3 Unit conversion: 1 ng/mL serum or RBC folate = 2.266 nmol/L.
4 The adjustment equation for serum creatinine is included in this table because this variable is often used in analyses that involve serum vitamin B-12,
total homocysteine, and MMA because of its confounding effect on these variables.
6S YETLEY AND JOHNSONcomparisons of the measurement procedures from the 2 surveys, or
comparable information on the traceability of both procedures to
a higher-order reference method, it is not possible to determine
whether these differences in folate and vitamin B-12 concentrations
between 2 neighboring countries with similar FA fortiﬁcation pro-
grams and food supplies are real or are due to differences in analytic
measurement procedures. A recent expert panel found similar chal-
lenges in the comparison of Canadian and US results from the 2
surveys for vitamin D biomarker data (67).
Comparability of NHANES results with published data is also
important for the use of cutoffs of adequacy to determine the
prevalence of at-risk groups. Cutoffs of nutritional status should
discriminate accurately between healthy and at-risk groups, with
few misclassiﬁcation errors. However, when one measurement
procedure is used to determine cutoffs, and users compare these
cutoffs with results from a different procedure, the generaliz-
ability of the cutoff value has questionable value (9, 15, 20).
Moreover, the selected cutoff can markedly affect prevalence
estimates. For example, the NHANES-based prevalence of low
serum vitamin B-12 for adults varied from 3% to 25%, and
depended on which cutoff the user applied from 3 commonly used
cutoffs of vitamin B-12 status (R Bailey, personal communication,
2011).
The appropriateness of commonly used cutoffs for the esti-
mation of the prevalence of at-risk groups from NHANES data
has been a consistent focus of expert panels since the ﬁrst folate-
based panel in 1984. Over the years, experts have identiﬁed a
variety of approaches to address this troublesome issue. A 1984
expert panel examined the effect on reference ranges for serum
and RBC folate concentrations after the deletion of data on
individuals with parameters that indicated folate deﬁciency (eg,
hemoglobin concentrations, mean corpuscular volume, macro-
cytosis) to identify serum and RBC folate concentration ranges
thatdifferedbetweensupposedlyat-riskandfolate-repletegroups
(15). This approach was not useful, perhaps because too few
persons had abnormalities in these hematologic parameters to
affect the results.
Another expert panel recommended the collection of serum
and whole-blood samples from patients with a folate-deﬁciency
diagnosis (eg, marrow abnormalities and response to folacin
treatments) and folate-replete populations in a clinical setting.
Panel members suggested the inclusion of these blood samples
in the NHANES analytic runs to help deﬁne a useful cutoff that
minimized misclassiﬁcation of healthy and at-risk NHANES
participants (15, 19). Survey logistics precluded implementation
of this approach.
For NHANES III (1988–1994), an expert panel recommended
handling the method dependence of the cutoff values similarly
to the mathematic adjustments that NCHS used to account for
differences in results between the Bio-Rad Quantaphase I and II
assay kits (20). Speciﬁcally, the panel recommended application
of the adjustment equation to the selected, commonly used
cutoffs, aswell asto theNHANES data.This adjustmentchanged
the original cutoffs of adequate folate status from ,6.8 to ,4.3
nmol/L for serum folate and from ,227 to ,155 nmol/L for
RBC folate. This cutoff adjustment decreased the estimated
prevalence of low serum folate concentrations from 26% to 8%
and low RBC folate concentrations from 12% to 4% (20).
Selhub et al (30) identiﬁed cutoffs by the determination of the
inﬂection point between circulating concentrations of folate or
vitamin B-12 (eg, serum and RBC folate, serum vitamin B-12)
and their respective functional indicators of status (eg, plasma
tHcy and MMA). From their results, they proposed a cutoff value
of ,10 nmol/L for serum folate and ,340 nmol/L for RBC
folate based on the lowest plasma tHcy. For serum vitamin B-12,
the cutoff would be ,150 pmol/L based on the lowest MMA
and ,300 pmol/L based on the lowest tHcy. Durazo-Arvizu et al
(68) used a similar approach to estimate the inﬂection point
between serum 25-hydroxyvitamin D and parathyroid hormone.
They showed that the statistical model researchers selected for
these types of analyses affected the derived cutoff value.
The preferred approach to the identiﬁcation of cutoff values is
to conduct clinical trials that allow direct comparison of bio-
marker concentrations with the appearance of adverse clinical
signs and symptoms, and in which the measurement procedure
is traceable to a higher-order reference method (4, 5, 58). Re-
searchers recognized all of the examples above as surrogates for
the preferred method of deﬁning cutoffs of adequacy and/or
safety but undertook them because of the absence of more robust
data at the time.
Effects of systematic bias
AccuracyisobviouslyimportantforNHANESforusessuchas
derivation of national reference intervals. Moreover, accuracy
issues can affect prevalence estimates of at-risk groups, for which
many researchers use NHANES data. For example, midway
through NHANES III (1988–1994), the NCEH began to use the
Bio-Rad Quantaphase II assay kit, instead of the Quantaphase I,
to measure serum and RBC folate (20).The systematic difference
between these 2 measurements required a statistical adjustment
to the Quantaphase I values to make them comparable with the
Quantaphase II results. Comparisons of the unadjusted with the
adjusted distribution curves for the Quantaphase I results pro-
duced differences of ’35% for serum and ’30% for RBC folate
(Table 3). If unadjusted cutoffs for low folate status (,6.8 nmol/L
for serum and ,226 nmol/L for RBC folate) had been used in
TABLE 3
Unadjusted and adjusted serum and red blood cell (RBC) folate values
for a sample population of individuals aged 20–39 y in NHANES III
(1988–1994)
1
Percentiles
Biomarker 5th 25th 50th 75th 95th Prevalence
nmol/L %
Serum folate
Unadjusted 6.3 10.2 14.0 21.1 38.3 6.5
Adjusted 4.1 6.6 9.3 14.0 25.8 8.1
RBC folate
Unadjusted 274 399 508 680 1008 1.9
Adjusted 193 281 360 485 725 4.3
1 The prevalence of the unadjusted low values for serum and RBC
folate concentrations were based on cutoffs for assessment of folate status
of ,6.8 nmol/L (3 ng/mL) for serum and ,227 nmol/L (100 ng/mL) for
RBC folate. The prevalence of the adjusted low values is based on cutoffs in
which the original cutoffs were adjusted by the same equation as was used
for the biomarker concentrations. The cutoffs that resulted were ,4.3 nmol/L
(1.9 ng/mL) for serum and ,155 nmol/L (68.5 ng/mL) for RBC folate. (Con-
version: 1 ng/mL = 2.266 nmol/L.) Adapted from reference 20.
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lence estimates of low serum folate and low RBC folate would
have been 26% and 12%, respectively (data not shown). With the
use of adjusted cutoff values with the adjusted biomarker con-
centration data, prevalence estimates of 8% for serum and 4% for
RBC folate were obtained (Table 3). The expert panel recom-
mended that the same adjustment be used for both the population-
based biomarker data and the cutoffs (20).
Within-person variance
Errors in prevalence estimates also occur when users fail to
adjust for within-person variability (WP) in biomarker measure-
ments (69). WP (ie, differences in measurement results within
a person between measurement periods) and between-person
variation(BP)arepartofbiologicalvariation.Ideally,usersshould
minimizeWPtoavoidmaskingorattenuationofthedifferencesof
interest, BP variabilities. Failure to adjust for WP can inappro-
priately inﬂate prevalence estimates of nutrient biomarkers. Al-
thoughWPadjustmenthasbecomecommonplaceindietaryintake
estimates, its use with nutrient biomarkers has been rare.
The estimation of WP and BP variations requires replicate
measures on given individuals. NHANES III (1988–1994) and
NHANES 1999–2002 collected replicate phlebotomies on a sub-
sample of adults (70, 71). The WP-to-BP ratio was ,1 for bio-
markers of interest in the assessment of folate and vitamin B-12
status (Table 4). However, even ratios of this size can affect
prevalence estimates (69). Except for serum vitamin B-12, the
WP-to-BPratioisquitesimilarforagivenbiomarkerbetweenthe
2 surveys. With the recent reporting of the NHANES 1999–2002
results on biological variation (71) and the earlier availability of
replicate results from NHANES III (1988–1994) (70), it is now
possible to consider their appropriateness and usewith the folate-
and vitamin B-12–related status biomarkers.
SUMMARY
NHANES has measured at least some biomarkers offolate and
vitaminB-12statusthroughoutitshistory,startingwithNHANESI
(1974–1975). Researchers and policymakers have used the results
for a broad range of policy and research applications. Over the
years, several expert panels have evaluated the measurement and
use of folate and vitamin B-12 status biomarkers. Key challenges
have included the effects of measurement procedures that changed
on the comparability of results over time and the appropriateness
of adequacy cutoffs for NHANES applications. The measurement
of folate and vitamin B-12 biomarkers in future NHANES will
beneﬁt from the evolving availability of well-documented refer-
ence methods and materials.
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